Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) will provide cannabis medicines for a major medical cannabis study project in the United Kingdom.

Project Twenty21 is Europe’s first and biggest national medical cannabis registry that was launched on November 7 at the Royal College of Psychiatrists in London. The project will enroll 20,000 patients by the end of 2021 for the study. The project aims to create the largest body of evidence for the efficacy of medical cannabis and convince UK policymakers that medical cannabis should be as widely available and affordable as other approved medicines for patients.

In addition, the study will support prescribers across the country to feel confident in providing medical cannabis to patients, while helping to build a case for NHS funding in seven key identified conditions. These conditions include chronic pain, epilepsy, multiple sclerosis, post-traumatic stress disorder, Tourette’s syndrome, and anxiety disorder. Further, the study will use real-world data to document the effectiveness, safety, quality of life, and patient-reported outcomes in that prescribed medical cannabis for these conditions.

It will not be a randomized control trial and all 20,000 participants will receive medical cannabis from participating providers at an affordable cost.

“We are excited to have this opportunity to participate in Project Twenty21 and help improve access to cannabis medicines in the UK. According to the Centre for Medicinal Cannabis, it is estimated that 1.4 million people in the UK are using illicit or ‘street cannabis’ to treat the symptoms of chronic conditions,” stated Tejinder Virk, president of Khiron Europe.

Project Twenty21 is backed by The Royal College of Psychiatrists, The British Pain Society, the United Patients Alliance, patients, and medical cannabis campaigners.